Compounds > metformin

metformin and imatinib mesylate

metformin has been researched along with imatinib mesylate in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's3 (37.50)24.3611
2020's3 (37.50)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chodorowski, Z; Hellmann, A; Prejzner, W; Sein Anand, J1
Choi, MK; Song, IS1
Gong, Y; Lin, J; Liu, X; Naren, D; Shi, F; Shi, R; Yan, T; Yang, X1
Boros, LG; Collins, TQ; D'Agostino, DP; Hitendra, P; Meuillet, EJ; Somlyai, G1
Cheng, H; Lau, CC; Nan, X; Qiu, B; Sheng, J; Wang, J; Wong, STC; Yin, Z; Yustein, JT; Zhao, H1
Gilreath, JA; Pokorny, R; Stenehjem, DD1
Gayatri, MB; Gundeti, S; Kancha, RK; Patchva, D; Reddy, ABM; Velugonda, N1

Reviews

2 review(s) available for metformin and imatinib mesylate

ArticleYear
Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences.
    Drug metabolism and pharmacokinetics, 2008, Volume: 23, Issue:4

    Topics: Animals; Benzamides; Cisplatin; Humans; Imatinib Mesylate; Kidney; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metformin; Organic Cation Transport Proteins; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Substrate Specificity

2008
Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma.
    Oncotarget, 2017, Jul-25, Volume: 8, Issue:30

    Topics: Atorvastatin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Metformin; Phenformin

2017

Other Studies

6 other study(ies) available for metformin and imatinib mesylate

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
[No influence of imatinib on type 2 diabetes].
    Przeglad lekarski, 2007, Volume: 64, Issue:4-5

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Imatinib Mesylate; Insulin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metformin; Middle Aged; Piperazines; Pyrimidines

2007
The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell.
    Anti-cancer drugs, 2015, Volume: 26, Issue:9

    Topics: Antineoplastic Agents; Autophagy; Benzamides; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Signaling System; Metformin; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured

2015
Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
    Cancer letters, 2020, 01-28, Volume: 469

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imatinib Mesylate; Male; Metformin; Mice; Oncogene Proteins, Fusion; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Protein c-fli-1; Proto-Oncogene Proteins c-akt; RNA-Binding Protein EWS; RNA-Seq; Sarcoma, Ewing; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2020
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:4

    Topics: Adult; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Metformin; Protein Kinase Inhibitors; Treatment Outcome

2022
Metformin exerts antileukemic effects by modulating lactate metabolism and overcomes imatinib resistance in chronic myelogenous leukemia.
    The FEBS journal, 2023, Volume: 290, Issue:18

    Topics: Adenosine Triphosphate; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Glucose; Humans; Imatinib Mesylate; Lactic Acid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Metformin

2023